Pioneers
We use our knowledge in HPV diagnostics realising an optimal cancer patient management.
Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer.
Our patented diagnostics support factors that are key to a favourable prognosis, such as early tumour detection and post-therapy patient management. As pioneers in HPV serology, we develop highly innovative solutions, including Prevo-Check®, the world´s first entire-body screening test for HPV16-induced cancer, which can be performed with a single drop of blood within minutes.
About
2020
New publication on Prevo-Check®:
Clinical efficacy of an antibody-based detection system for human papilloma virus infection in oral squamous cell carcinoma.
Find out more about the study here.
Abviris has been voted into the Top 25 of the FOCUS Innovation Prize, a national competition run by one of the three most widely circulated weeklies in Germany.
The competition was judged by a high calibre panel including Jens Spahn, Germany’s Federal Minister of Health.
Findings from a multicentre European clinical study evaluating the DRH1 tumour marker test have been published in Ebiomedicine, one of the Lancet’s stable of medical journals. Find out more about the study here.
2019
Study with Prevo-Check® wins “Pilot of the Year” UK Diagnostics Award
GALS project kick-off for development of US market access strategy
Kick-off for cooperation between Abviris and DermaMed
Establishment of Advisory Board
2018
Launch of business development
> 5000 study patients enrolled
2016
2015
> 1500 patients tested in 4 clinical trials
Test market for Prevo-Check® in Germany
International 1st clinical trial
2014
